vs
BWX Technologies, Inc.（BWXT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
BWX Technologies, Inc.的季度营收约是Royalty Pharma plc的1.4倍（$885.8M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 10.5%，领先23.9%），BWX Technologies, Inc.同比增速更快（18.7% vs 4.8%），过去两年BWX Technologies, Inc.的营收复合增速更高（21.1% vs 4.6%）
BWX Technologies Inc.（简称BWXT）总部位于美国弗吉尼亚州林奇堡，是一家面向全球供应核部件与核燃料的专业企业，产品广泛应用于核电及核工业相关领域，服务覆盖全球多个国家和地区的客户。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
BWXT vs RPRX — 直观对比
营收规模更大
BWXT
是对方的1.4倍
$622.0M
营收增速更快
BWXT
高出13.9%
4.8%
净利率更高
RPRX
高出23.9%
10.5%
两年增速更快
BWXT
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $885.8M | $622.0M |
| 净利润 | $93.0M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 10.4% | 62.4% |
| 净利率 | 10.5% | 34.4% |
| 营收同比 | 18.7% | 4.8% |
| 净利润同比 | 30.9% | 2.9% |
| 每股收益（稀释后） | $1.02 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BWXTRPRX
| Q4 25 | $885.8M | $622.0M | ||
| Q3 25 | $866.3M | $609.3M | ||
| Q2 25 | $764.0M | $578.7M | ||
| Q1 25 | $682.3M | $568.2M | ||
| Q4 24 | $746.3M | $593.6M | ||
| Q3 24 | $672.0M | $564.7M | ||
| Q2 24 | $681.5M | $537.3M | ||
| Q1 24 | $604.0M | $568.0M |
净利润BWXTRPRX
| Q4 25 | $93.0M | $214.2M | ||
| Q3 25 | $82.1M | $288.2M | ||
| Q2 25 | $78.4M | $30.2M | ||
| Q1 25 | $75.5M | $238.3M | ||
| Q4 24 | $71.0M | $208.2M | ||
| Q3 24 | $69.5M | $544.0M | ||
| Q2 24 | $73.0M | $102.0M | ||
| Q1 24 | $68.5M | $4.8M |
毛利率BWXTRPRX
| Q4 25 | — | — | ||
| Q3 25 | 21.8% | — | ||
| Q2 25 | 25.1% | — | ||
| Q1 25 | 24.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | 24.7% | — | ||
| Q1 24 | 24.6% | — |
营业利润率BWXTRPRX
| Q4 25 | 10.4% | 62.4% | ||
| Q3 25 | 13.1% | 70.1% | ||
| Q2 25 | 13.4% | 36.3% | ||
| Q1 25 | 14.2% | 94.0% | ||
| Q4 24 | 12.4% | 60.9% | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 14.5% | 50.2% | ||
| Q1 24 | 15.4% | -13.0% |
净利率BWXTRPRX
| Q4 25 | 10.5% | 34.4% | ||
| Q3 25 | 9.5% | 47.3% | ||
| Q2 25 | 10.3% | 5.2% | ||
| Q1 25 | 11.1% | 41.9% | ||
| Q4 24 | 9.5% | 35.1% | ||
| Q3 24 | 10.3% | 96.3% | ||
| Q2 24 | 10.7% | 19.0% | ||
| Q1 24 | 11.3% | 0.8% |
每股收益（稀释后）BWXTRPRX
| Q4 25 | $1.02 | $0.49 | ||
| Q3 25 | $0.89 | $0.67 | ||
| Q2 25 | $0.85 | $0.07 | ||
| Q1 25 | $0.82 | $0.55 | ||
| Q4 24 | $0.77 | $0.46 | ||
| Q3 24 | $0.76 | $1.21 | ||
| Q2 24 | $0.79 | $0.23 | ||
| Q1 24 | $0.75 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $499.8M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.2B | $9.7B |
| 总资产 | $4.3B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资BWXTRPRX
| Q4 25 | $499.8M | $618.7M | ||
| Q3 25 | $79.6M | $938.9M | ||
| Q2 25 | $37.0M | $631.9M | ||
| Q1 25 | $55.4M | $1.1B | ||
| Q4 24 | $74.1M | $929.0M | ||
| Q3 24 | $35.5M | $950.1M | ||
| Q2 24 | $48.3M | $1.8B | ||
| Q1 24 | $45.9M | $843.0M |
总债务BWXTRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益BWXTRPRX
| Q4 25 | $1.2B | $9.7B | ||
| Q3 25 | $1.2B | $9.6B | ||
| Q2 25 | $1.2B | $9.5B | ||
| Q1 25 | $1.1B | $9.8B | ||
| Q4 24 | $1.1B | $10.3B | ||
| Q3 24 | $1.1B | $10.3B | ||
| Q2 24 | $998.5M | $9.8B | ||
| Q1 24 | $946.2M | $9.9B |
总资产BWXTRPRX
| Q4 25 | $4.3B | $19.6B | ||
| Q3 25 | $3.8B | $19.3B | ||
| Q2 25 | $3.7B | $18.3B | ||
| Q1 25 | $3.1B | $17.6B | ||
| Q4 24 | $2.9B | $18.2B | ||
| Q3 24 | $2.9B | $18.0B | ||
| Q2 24 | $2.8B | $17.7B | ||
| Q1 24 | $2.8B | $16.1B |
负债/权益比BWXTRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $127.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $56.8M | — |
| 自由现金流率自由现金流/营收 | 6.4% | — |
| 资本支出强度资本支出/营收 | 7.9% | — |
| 现金转化率经营现金流/净利润 | 1.37× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $295.3M | — |
8季度趋势，按日历期对齐
经营现金流BWXTRPRX
| Q4 25 | $127.0M | $827.1M | ||
| Q3 25 | $143.2M | $702.6M | ||
| Q2 25 | $159.0M | $364.0M | ||
| Q1 25 | $50.6M | $596.1M | ||
| Q4 24 | $276.9M | $742.5M | ||
| Q3 24 | $32.6M | $703.6M | ||
| Q2 24 | $65.9M | $658.2M | ||
| Q1 24 | $33.0M | $664.6M |
自由现金流BWXTRPRX
| Q4 25 | $56.8M | — | ||
| Q3 25 | $94.9M | — | ||
| Q2 25 | $126.3M | — | ||
| Q1 25 | $17.3M | — | ||
| Q4 24 | $224.4M | — | ||
| Q3 24 | $-7.7M | — | ||
| Q2 24 | $35.5M | — | ||
| Q1 24 | $2.6M | — |
自由现金流率BWXTRPRX
| Q4 25 | 6.4% | — | ||
| Q3 25 | 11.0% | — | ||
| Q2 25 | 16.5% | — | ||
| Q1 25 | 2.5% | — | ||
| Q4 24 | 30.1% | — | ||
| Q3 24 | -1.1% | — | ||
| Q2 24 | 5.2% | — | ||
| Q1 24 | 0.4% | — |
资本支出强度BWXTRPRX
| Q4 25 | 7.9% | — | ||
| Q3 25 | 5.6% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 4.9% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 4.5% | — | ||
| Q1 24 | 5.0% | — |
现金转化率BWXTRPRX
| Q4 25 | 1.37× | 3.86× | ||
| Q3 25 | 1.74× | 2.44× | ||
| Q2 25 | 2.03× | 12.06× | ||
| Q1 25 | 0.67× | 2.50× | ||
| Q4 24 | 3.90× | 3.57× | ||
| Q3 24 | 0.47× | 1.29× | ||
| Q2 24 | 0.90× | 6.45× | ||
| Q1 24 | 0.48× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BWXT
| Nuclear Component Program | $436.4M | 49% |
| Nuclear Manufacturing | $134.8M | 15% |
| Cost Plus Fee | $116.1M | 13% |
| Uranium And Nuclear Services | $103.8M | 12% |
| Commercial Operations | $49.0M | 6% |
| Commercial Operations Segment | $33.7M | 4% |
| Transferred At Point In Time | $1.3M | 0% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
